← All trials
NCT04567810
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2020
- Primary completion
- Dec 14, 2020
- Completion date
- Dec 14, 2020
- First posted
- Sep 29, 2020
- Last posted
- Dec 21, 2020
- Enrollment
- 48
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityStudy director
- Linear Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.